PMID- 32938975
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210916
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Sep 16
TI  - Treatment of non-erosive reflux disease and dynamics of the esophageal 
      microbiome: a prospective multicenter study.
PG  - 15154
LID - 10.1038/s41598-020-72082-8 [doi]
LID - 15154
AB  - Non-erosive reflux disease (NERD) pathogenesis has not been thoroughly evaluated. 
      Here, we assessed the response of patients with NERD to proton pump inhibitor 
      (PPI) therapy; changes in the microbiome and biologic marker expression in the 
      esophageal mucosa were also evaluated. Patients with NERD (n = 55) received 
      esomeprazole (20 mg) for eight weeks. The treatment response was evaluated at 
      baseline, week four, and week eight. Esophageal mucosal markers and oropharyngeal 
      and esophageal microbiomes were analyzed in patients who underwent upper 
      gastrointestinal endoscopy at screening (n = 18). Complete and partial response 
      rates at week eight were 60.0% and 32.7% for heartburn, and 61.8% and 29.1% for 
      regurgitation, respectively. The expressions of several inflammatory cytokines, 
      including IL-6, IL-8, and NF-kappaB, were decreased at week eight. Streptococcus, 
      Haemophilus, Prevotella, Veillonella, Neisseria, and Granulicatella were 
      prevalent regardless of the time-point (baseline vs. week eight) and organ 
      (oropharynx vs. esophagus). The overall composition of oropharyngeal and 
      esophageal microbiomes showed significant difference (P = 0.004), which 
      disappeared after PPI therapy. In conclusion, half-dose PPI therapy for eight 
      weeks could effectively control NERD symptoms. The expression of several 
      inflammatory cytokines was reduced in the esophagus, and oropharyngeal and 
      esophageal microbiomes in patients with NERD showed significant difference. 
      However, the microbial compositions in the oropharynx and esophagus were not 
      affected by PPI therapy in this study. Impact of PPI on the microbiome in 
      patients with NERD should be more investigated in future studies.
FAU - Park, Chan Hyuk
AU  - Park CH
AD  - Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang 
      University College of Medicine, Guri, Republic of Korea.
FAU - Seo, Seung In
AU  - Seo SI
AD  - Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym 
      University College of Medicine, Seoul, Republic of Korea.
FAU - Kim, Joon Sung
AU  - Kim JS
AD  - Division of Gastroenterology, Department of Internal Medicine, College of 
      Medicine, Incheon St Mary's Hospital, The Catholic University of Korea, Seoul, 
      Republic of Korea.
FAU - Kang, Sun Hyung
AU  - Kang SH
AD  - Department of Internal Medicine, Chungnam National University School of Medicine, 
      Daejeon, Republic of Korea.
FAU - Kim, Beom Jin
AU  - Kim BJ
AD  - Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Choi, Yoon Jin
AU  - Choi YJ
AD  - Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic 
      of Korea.
AD  - Department of Internal Medicine, Yonsei Institute of Gastroenterology, Severance 
      Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
FAU - Byun, Hyo Joo
AU  - Byun HJ
AD  - Department of Internal Medicine, Yonsei Institute of Gastroenterology, Severance 
      Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seoul, 03722, 
      Republic of Korea.
AD  - Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, 
      Republic of Korea.
FAU - Yoon, Jung-Ho
AU  - Yoon JH
AD  - Department of Internal Medicine, Yonsei Institute of Gastroenterology, Severance 
      Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seoul, 03722, 
      Republic of Korea.
AD  - Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, 
      Republic of Korea.
FAU - Lee, Sang Kil
AU  - Lee SK
AD  - Department of Internal Medicine, Yonsei Institute of Gastroenterology, Severance 
      Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seoul, 03722, 
      Republic of Korea. sklee@yuhs.ac.
AD  - Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, 
      Republic of Korea. sklee@yuhs.ac.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200916
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Proton Pump Inhibitors)
RN  - N3PA6559FT (Esomeprazole)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/metabolism
MH  - Cytokines/metabolism
MH  - Esomeprazole/therapeutic use
MH  - Esophageal Mucosa/metabolism/microbiology
MH  - Esophagus/metabolism/*microbiology
MH  - Female
MH  - Gastroesophageal Reflux/*drug therapy/metabolism/*microbiology
MH  - *Gastrointestinal Microbiome/drug effects
MH  - Humans
MH  - Inflammation Mediators/metabolism
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/therapeutic use
PMC - PMC7494862
COIS- The authors declare no competing interests.
EDAT- 2020/09/18 06:00
MHDA- 2020/12/22 06:00
PMCR- 2020/09/16
CRDT- 2020/09/17 05:40
PHST- 2020/02/24 00:00 [received]
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/09/17 05:40 [entrez]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
PHST- 2020/09/16 00:00 [pmc-release]
AID - 10.1038/s41598-020-72082-8 [pii]
AID - 72082 [pii]
AID - 10.1038/s41598-020-72082-8 [doi]
PST - epublish
SO  - Sci Rep. 2020 Sep 16;10(1):15154. doi: 10.1038/s41598-020-72082-8.